Bridge Point Capital Hosted Its Open House Launch Party Event in New York

Manhattan, New York, February 19th, 2020 - Bridge Point Capital hosted an Open House with the Family Offices to discuss Healthcare Investment opportunities at its new headquarters at Carnegie Tower Hall, New York. Many well-known family offices, investors and industry experts attended the event to share experiences on investment strategies in the healthcare industry in 2020.

The event focused on the discussion of the latest trends in the healthcare industry this year and began with a discussion of the impact of the coronavirus (COVID-19) outbreak on the landscape of the industry. Participants discussed novel investment strategies and models to accommodate the expected changes in the industry. A lot of the discussions focused on how capital could be more efficiently directed to cultivating the development of promising healthcare technology, and how the efficiency of commercializing technology can be beneficial for people’s lives.

Ms. Rosemary Sagar, Chief Investment Officer of Kingdon Foundation, discussed the investment strategy of her foundatyion and how family offices can gain access to their funds. Throughout her 15 years at Kingdon Foundation, Ms. Sagar has been committed to seeking innovative and successful emerging managers as their investment targets. The investment focus includes hedge fund, private equity, venture capital, real estate fund and direct investment projects. Ms. Sagar pointed out that communication and cooperation between family offices serve a crucial role in improving the efficiency of fund management and maximizing return. The co-investment platform model has been adopted by more and more family offices, and it holds unique advantages in terms of risk-sharing and choosing portfolio projects. In addition, co-investment platforms are more favorable for resource sharing and integration, thereby facilitating the development of portfolio companies and enhancing return.

Mr. Joe Sun, CEO of Capital Impetus Group, gave an in-depth analysis of recent trends in U.S.-China cross-border healthcare transactions. He pointed out in particular that China's healthcare industry is attracting enormous attention from the investment field. The successful landing of a product into the Chinese market is extremely positive news from the investors’ perspective. Mr. Sun suggested that family offices who are interested in the Chinese market will need a good understanding of the Chinese culture and regulatory measures, since the way capital markets operate in China and the U.S. are very different. Seeking a value-added partner with rich cross-border experience and resources is crucial for a company’s commercial success in the Chinese market.

Mr. Mark Young, co-founder of Bridge Point Capital, discussed emerging investment opportunities in the healthcare industry. He pointed out that investors should not only see the opportunities brought by the short-term demand that emerged from the coronavirus epidemic, but also how the epidemic may reshape the habits of the Chinese people in the long term. In the future, innovative air and environmental disinfection technologies will develop rapidly in China. Mr. Young pointed out that Bridge Point Capital is committed to supporting the promotion and adoption of disruptive technologies around the globe. In the field of sanitization and disinfection, Bridge Point Capital is actively working with a technology company to bring a safe, effective, and long-acting disinfection product that will fill a product gap in the Chinese market.

Throughout the event, Bridge Point Capital was able to contribute to the ongoing discussions on investment strategies in the healthcare space, offering its expertise and advice on cross-border transactions, integration and expansion for healthcare corporations.

About us:

Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast yet unexplored Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to establish a sustainable investment platform for our investors.